Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00800267 · ClinicalTrials.gov registry record · Phase 3
A Study of Glaucoma or Ocular Hypertension in Patients Within the United States
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 418
- Enrollment target
NCT00800267 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 418 participants.
The verdict
NCT00800267, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 418 participants
- Enrollment target
Study Summary
Safety and efficacy study comparing between fixed combination latanoprost-timolol and its component parts.
Interventions
- DRUG latanoprost 0.005%
- DRUG timolol 0.5%
- DRUG fixed combination latanoprost-timolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 1997-07 |
| Est. Completion | 1999-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00800267
The ClinicalTrials.gov registry entry for NCT00800267 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which latanoprost 0.005% is the first listed.
NCT00800267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00800267 about?
NCT00800267 is a clinical study titled "A Study of Glaucoma or Ocular Hypertension in Patients Within the United States". Safety and efficacy study comparing between fixed combination latanoprost-timolol and its component parts.
What is the current status of trial NCT00800267?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 418 participants. The study started on 1997-07. Estimated completion is 1999-06.
What interventions are being tested in trial NCT00800267?
The interventions under investigation include: latanoprost 0.005% (DRUG), timolol 0.5% (DRUG), fixed combination latanoprost-timolol (DRUG).
Who is sponsoring clinical trial NCT00800267?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.